查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球带因者筛检市场（~2028）：按产品和服务类型（扩展（客製化/预设计）/目标疾病）/疾病（血液/肺）/技术（DNA 序列/PCR）/最终用户/地区
市场调查报告书
商品编码
1421503

全球带因者筛检市场（~2028）：按产品和服务类型（扩展（客製化/预设计）/目标疾病）/疾病（血液/肺）/技术（DNA 序列/PCR）/最终用户/地区

Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases), Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 224 Pages | 订单完成后即时交付

价格
简介目录

报告摘要

全球带因者筛检市场规模预计将从 2023 年的 22 亿美元成长到 2028 年的 54 亿美元，预测期内复合年增长率为 19.7%。

市场驱动因素包括基因检测技术的持续进步，例如次世代定序（NGS），使携带者筛检更加高效、准确和具有成本效益；流行率的增加部分是由于对各种疾病的遗传基础有了更好的了解疾病。

调查范围
调查年份 2021-2028
基准年 2022年
预测期 2023-2028
单元 金额（美元）
部分 产品和服务类型/疾病/技术/最终用户/地区
目标区域 北美（美国、加拿大）、欧洲（德国、法国、英国、西班牙、义大利等）、亚太地区（中国、印度、日本等）、其他地区（拉丁美洲、中东和非洲、海湾合作委员会国家）

按疾病划分，神经系统疾病类别预计在预测期内将占据第二大份额。了解亨廷顿舞蹈症、肌萎缩侧索硬化症 (ALS) 和癫痫等疾病的遗传基础对于评估将这些疾病遗传给后代的风险至关重要。同样，神经系统疾病的带因者筛检可以及早发现遗传风险因子。早期识别携带者为个人和夫妇提供了一个机会，可以在计划过程的早期做出明智的生殖决定并考虑干预和治疗。

从技术来看，PCR技术领域占据第二大份额。 PCR技术以其在扩增和检测特定DNA序列方面的高灵敏度和特异性而闻名。这种准确性对于携带者筛检以可靠地识别与各种疾病相关的基因突变携带者至关重要。同样，PCR 允许在一次反应中扩增多个目标 DNA 序列，这一特性称为多重分析。这种能力在职业筛检中很有价值。

该报告调查了全球职业筛检市场，并提供了市场概况、市场影响因素和市场机会分析、技术和专利趋势、法律制度、市场规模趋势和预测，以及各个细分市场和地区的详细资讯。我们编译分析，竞争形势、主要企业概况等。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 趋势
  • 价格分析
  • 价值链分析
  • 供应链分析
  • 波特五力分析
  • 生态系/市场地图
  • 关税和监管状况
  • 专利分析
  • 影响客户业务的趋势/干扰
  • 重大会议及活动
  • 技术分析
  • 主要相关利益者和采购标准
  • 贸易分析

第六章职业筛检市场：依产品/服务分类

  • 服务
  • 产品

第七章职业筛检市场：依类型

  • 扩大职业筛检
    • 预先设计的面板测试
    • 客製化面板测试
  • 目标疾病携带者筛检

第八章 携带者筛检市场：依疾病分类

  • 肺部疾病
  • 血液疾病
  • 神经系统疾病
  • 其他的

第九章职业筛检市场：依技术分类

  • DNA定序
  • PCR
  • DNA微阵列
  • 其他的

第 10 章 职业筛检市场：依最终使用者分类

  • 医院/医疗中心
  • 临床实验室
  • 不孕不育诊所
  • 其他的

第十一章职业筛检市场：按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第十二章竞争形势

  • 概述
  • 主要策略/主要企业
  • 市场占有率分析
  • 收益占有率分析
  • 企业评价矩阵
  • 新兴企业/小型企业评估矩阵
  • 竞争格局及趋势

第十三章 公司简介

  • 主要企业
    • NATERA, INC.
    • QUEST DIAGNOSTICS INCORPORATED
    • FULGENT GENETICS
    • INVITAE CORPORATION
    • EUROFINS SCIENTIFIC
    • OPKO HEALTH, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • MYRIAD GENETICS, INC.
    • ILLUMINA, INC.
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • CENTOGENE NV
    • DIASORIN SPA
    • BGI
    • OTOGENETICS
    • GENETECH
  • 其他公司
    • OXY-GEN LABORATORY LLC
    • MEDGENOME
    • AMBRY GENETICS.
    • ASPER BIOGENE
    • LIFELABS GENETICS
    • EASYDNA
    • LIFECELL
    • CNC PATH LAB
    • SIGNATURE DIAGNOSTICS INC.
    • MITERA

第十四章附录

简介目录
Product Code: MD 7435

Report Description

The global Carrier Screening Market is expected to reach USD 5.4 Billion by 2028 from USD 2.2 Billion in 2023, at a CAGR of 19.7% during the forecast period. Market is driven by factors such as Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS), improve the efficiency, accuracy, and cost-effectiveness of carrier screening, The increasing prevalence of genetic disorders, coupled with a greater understanding of the genetic basis of various conditions On the other hand, The demand for genetic counseling services often exceeds the available resources. A shortage of genetic counselors can hinder the delivery of comprehensive counseling to individuals undergoing carrier screening, potentially limiting the understanding and interpretation of results.

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsProduct & Service, Type, Medical Condition, Technology, End User, and Region
Regions coveredNorth America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World (Latin America, Middle East & Africa, GCC countries)

"The Neurological Conditions accounted for the second largest market share in the carrier screening market product' s market, during the forecast period"

Based on the Medical Conditions, Carrier Screening Market is classified into Hematologic Conditions, Pulmonary Conditions, Neurological Conditions, and Others. In 2022, Neurological Conditions accounted for a sizable market share because Many neurological disorders have a genetic component. Understanding the genetic basis of conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy can be crucial for assessing the risk of passing on these conditions to future generations. Likewise, Carrier screening for neurological conditions allows for early detection of genetic risk factors. Early identification of carriers provides an opportunity for individuals and couples to make informed reproductive decisions and consider interventions or therapies early in the planning stages.

"PCR technology segment accounted for the second largest market share"

Based on type on technology, the carrier screening market is segmented into DNA Sequencing, PCR, DNA Microarray, and Other. The PCR technology segment accounted for the second largest market share in 2022., due to its variety of applications such as PCR technology is known for its high sensitivity and specificity in amplifying and detecting specific DNA sequences. This accuracy is crucial in carrier screening to reliably identify carriers of genetic mutations associated with various disorders, likewise, PCR allows for the amplification of multiple target DNA sequences in a single reaction, a feature known as multiplexing. This capability is valuable in carrier screening,

"APAC region accounted for the third highest CAGR"

The global Carrier Screening market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a considerable market share in 2022 and the future. The Asia-Pacific market is being propelled by an rising cases of rare disease, rising in healthcare expenditure, rising in awareness about early disease diagnosis.

"Europe is estimated to register the second highest CAGR during the forecast period."

In this report, the Carrier Screening market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the second highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of genetic and rare diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies such as carrier screening.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%

Lits of Companies Profiled in the Report:

Invitae Corporation. (US)

Fulgent Genetics.(US)

Eurofins Scientific (Germany)

OPKO Health, Inc.(US)

Thermo Fisher Scientific Inc.(US)

Quest Diagnostics Incorporated (US)

Myriad Genetics, Inc (US)

Illumina, Inc.(US)

Natera, Inc.(Italy)

Laboratory Corporation of America Holdings.(US)

CENTOGENE N.V.(Germany)

DiaSorin S.p.A.(Italy)

BGI (China)

Otogenetics (US)

GeneTech (India)

Signature Diagnostics Inc.(US)

MedGenome (US)

Ambry Genetics.(US)

Asper Biogene (Estonia)

LifeLabs Genetics (Canada)

EasyDNA (US)

LifeCell (India)

CNC Path Lab (India)

Oxy-Gen Laboratory LLC (US)

Mitera (US)

Research Coverage:

This report studies the Carrier Screening market based on Product & Service, Type, Medical Condition, Technology, End User, and Region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Carrier Screening market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.

Market Penetration: Comprehensive information on Carrier Screening Market products offered by the top 25 players in the market. The report analyses the Carrier Screening market by Product & Service, Type, Medical Condition, Technology, End User, and Region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Carrier Screening market

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Carrier Screening market

Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS & EXCLUSIONS
  • 1.4 MARKET SCOPE
    • 1.4.1 MARKETS COVERED
    • 1.4.2 REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES
    • 1.6.1 RECESSION IMPACT: CARRIER SCREENING MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • FIGURE 2 KEY SECONDARY SOURCES
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primary interviews
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET ESTIMATION
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • FIGURE 7 MARKET SIZE ESTIMATION: CARRIER SCREENING MARKET
    • 2.2.2 GROWTH FORECAST
    • FIGURE 8 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
    • FIGURE 9 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH LIMITATIONS
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT: CARRIER SCREENING MARKET
  • 2.8 IMPACT OF ECONOMIC RECESSION ON CARRIER SCREENING MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 11 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CARRIER SCREENING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 CARRIER SCREENING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 15 CARRIER SCREENING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 CARRIER SCREENING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 CARRIER SCREENING MARKET OVERVIEW
    • FIGURE 17 GROWING PREVALENCE OF GENETIC DISORDERS TO DRIVE MARKET
  • 4.2 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2023-2028
    • FIGURE 18 PREDESIGNED PANEL TESTING SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.3 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE AND COUNTRY, 2023
    • FIGURE 19 US AND PRODUCTS TO DOMINATE NORTH AMERICAN CARRIER SCREENING MARKET IN 2023
  • 4.4 GEOGRAPHICAL GROWTH OPPORTUNITIES: CARRIER SCREENING MARKET
    • FIGURE 20 US TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: CARRIER SCREENING MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing emphasis on early disease detection and prevention
      • 5.2.1.2 Growing prevalence of genetic disorders
      • 5.2.1.3 High risk of chromosomal abnormalities with advancing maternal age
    • TABLE 2 GLOBAL INCIDENCE RATE OF TRISOMY
      • 5.2.1.4 Increased focus on preconception and prenatal testing
      • 5.2.1.5 Rising number of fertility clinics and IVF centers
      • 5.2.1.6 Declining rate of fertility
    • TABLE 3 FERTILITY RATE (BIRTHS PER WOMAN), BY COUNTRY
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Ethical concerns in preconception genetic carrier screening
      • 5.2.2.2 High cost of carrier screening
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased awareness about reproductive health in emerging economies
    • FIGURE 22 HEALTHCARE EXPENDITURE PER CAPITA IN BRICS, 2012-2020
      • 5.2.3.2 Integration with telehealth and digital health platforms
      • 5.2.3.3 Increased number of collaborations and partnerships among healthcare organizations
      • 5.2.3.4 Increasing number of government initiatives and policies toward genetic health improvement
      • 5.2.3.5 Growing focus on health screening for rare diseases
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of skilled professionals
      • 5.2.4.2 Lack of standard guidelines for carrier screening
  • 5.3 TRENDS
    • 5.3.1 LACK OF PUBLIC INTEREST IN EXPANDED CARRIER SCREENING
  • 5.4 PRICING ANALYSIS
    • TABLE 4 INDICATIVE PRICING OF CARRIER SCREENING PRODUCTS/SERVICES
    • TABLE 5 AVERAGE SELLING PRICE OF PREIMPLANTATION GENETIC TESTING SYSTEMS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 24 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 PORTER'S FIVE FORCES: CARRIER SCREENING MARKET
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF SUPPLIERS
    • 5.7.4 BARGAINING POWER OF BUYERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 ECOSYSTEM/MARKET MAP
    • FIGURE 25 ECOSYSTEM/MARKET MAP: CARRIER SCREENING MARKET
    • TABLE 7 ROLE IN ECOSYSTEM: CARRIER SCREENING MARKET
    • FIGURE 26 KEY PLAYERS IN CARRIER SCREENING MARKET
  • 5.9 TARIFF & REGULATORY LANDSCAPE
    • TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING CARRIER SCREENING MARKET
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
      • 5.9.2.1 UK
      • 5.9.2.2 France
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 Japan
      • 5.9.3.2 India
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENT TRENDS FOR CARRIER SCREENING
    • FIGURE 27 PATENT TRENDS FOR CARRIER SCREENING, JANUARY 2013-DECEMBER 2023
    • 5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
    • FIGURE 28 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR CARRIER SCREENING PATENTS, JANUARY 2013- DECEMBER 2023
  • 5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.11.1 REVENUE SHIFT AND REVENUE POCKETS FOR CARRIER SCREENING MANUFACTURERS
    • FIGURE 29 REVENUE SHIFT FOR CARRIER SCREENING PRODUCTS/SERVICES
  • 5.12 KEY CONFERENCES & EVENTS
    • TABLE 9 DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
  • 5.13 TECHNOLOGY ANALYSIS
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS
    • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS
    • TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CARRIER SCREENING PRODUCTS (%)
    • 5.14.2 BUYING CRITERIA
    • FIGURE 31 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
    • TABLE 11 KEY BUYING CRITERIA FOR END USERS OF CARRIER SCREENING PRODUCTS/SERVICES
  • 5.15 TRADE ANALYSIS
    • TABLE 12 IMPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 13 EXPORT DATA FOR HS CODE 901849, BY COUNTRY, 2018-2022 (USD MILLION)

6 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 14 CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 SERVICES
    • 6.2.1 RISING NUMBER OF ACCREDITED LABORATORIES AND GENETIC CASES TO DRIVE MARKET
    • TABLE 15 CARRIER SCREENING MARKET FOR SERVICES, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 PRODUCTS
    • 6.3.1 GROWING INCIDENCE OF CHROMOSOMAL ABNORMALITIES AND RISING USE OF CARRIER SCREENING TESTS TO DRIVE MARKET
    • TABLE 16 KEY PLAYERS PROVIDING CARRIER SCREENING PRODUCTS
    • TABLE 17 CARRIER SCREENING MARKET FOR PRODUCTS, BY REGION, 2021-2028 (USD MILLION)

7 CARRIER SCREENING MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 18 CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 EXPANDED CARRIER SCREENING
    • TABLE 19 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 20 CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1 PREDESIGNED PANEL TESTING
      • 7.2.1.1 Predesigned panel testing segment to command larger market share during forecast period
    • TABLE 21 PREDESIGNED PANEL TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2 CUSTOMIZED PANEL TESTING
      • 7.2.2.1 Better customization options for meeting specific customer requirements to drive segment
    • TABLE 22 CUSTOMIZED PANEL TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 TARGETED DISEASE CARRIER SCREENING
    • 7.3.1 INTRODUCTION OF PANELS FOR SIMULTANEOUSLY SCREENING MULTIPLE GENETIC CONDITIONS TO DRIVE MARKET
    • TABLE 23 CARRIER SCREENING MARKET FOR TARGETED DISEASE CARRIER SCREENING, BY REGION, 2021-2028 (USD MILLION)

8 CARRIER SCREENING MARKET, BY MEDICAL CONDITION

  • 8.1 INTRODUCTION
    • TABLE 24 CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
  • 8.2 PULMONARY CONDITIONS
    • 8.2.1 INCREASING AWARENESS ABOUT CYSTIC FIBROSIS IN REPRODUCTIVE PLANNING TO DRIVE MARKET
    • TABLE 25 LIVE BIRTH INCIDENCE OF CYSTIC FIBROSIS
    • TABLE 26 CARRIER SCREENING PRODUCTS/SERVICES FOR CYSTIC FIBROSIS
    • TABLE 27 CARRIER SCREENING MARKET FOR PULMONARY CONDITIONS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 HEMATOLOGICAL CONDITIONS
    • 8.3.1 RISING PREVALENCE OF HEMATOLOGICAL DISORDERS AMONG INFANTS TO DRIVE MARKET
    • TABLE 28 CARRIER SCREENING MARKET FOR HEMATOLOGICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 NEUROLOGICAL CONDITIONS
    • 8.4.1 INCREASED AWARENESS OF NEUROLOGICAL SCREENING AND PRESENCE OF TARGETED SCREENING PANELS TO DRIVE MARKET
    • TABLE 29 GLOBAL PREVALENCE OF NEUROLOGICAL CONDITIONS
    • TABLE 30 CARRIER SCREENING PRODUCTS/SERVICES FOR NEUROLOGICAL CONDITIONS
    • TABLE 31 CARRIER SCREENING MARKET FOR NEUROLOGICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER MEDICAL CONDITIONS
    • TABLE 32 CARRIER SCREENING MARKET FOR OTHER MEDICAL CONDITIONS, BY REGION, 2021-2028 (USD MILLION)

9 CARRIER SCREENING MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
    • TABLE 33 CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 9.2 DNA SEQUENCING
    • 9.2.1 DNA SEQUENCING SEGMENT TO DOMINATE MARKET DURING STUDY PERIOD
    • TABLE 34 DNA SEQUENCING USED BY MARKET PLAYERS
    • TABLE 35 CARRIER SCREENING MARKET FOR DNA SEQUENCING, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 PCR
    • 9.3.1 HIGH ACCURACY, LOW REACTION TIME, AND ABSOLUTE ESTIMATION OF TARGET MOLECULE TO DRIVE MARKET
    • TABLE 36 PCR USED BY MARKET PLAYERS
    • TABLE 37 CARRIER SCREENING MARKET FOR PCR, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 DNA MICROARRAYS
    • 9.4.1 ABILITY TO ANALYZE MULTIPLE GENETIC MARKERS IN SINGLE ASSAY TO DRIVE MARKET
    • TABLE 38 DNA MICROARRAYS USED BY MARKET PLAYERS
    • TABLE 39 CARRIER SCREENING MARKET FOR DNA MICROARRAYS, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 OTHER TECHNOLOGIES
    • TABLE 40 ADVANTAGES OF OTHER TECHNOLOGIES FOR CARRIER SCREENING
    • TABLE 41 CARRIER SCREENING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

10 CARRIER SCREENING MARKET, BY END USER

  • 10.1 INTRODUCTION
    • TABLE 42 CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.2 HOSPITALS AND MEDICAL CENTERS
    • 10.2.1 RISING PATIENT POPULATION AND INCREASING MEDICARE REIMBURSEMENT FOR CLINICAL TESTS TO DRIVE SEGMENT
    • TABLE 43 CARRIER SCREENING MARKET FOR HOSPITALS AND MEDICAL CENTERS, BY REGION, 2021-2028 (USD MILLION)
  • 10.3 CLINICAL LABORATORIES
    • 10.3.1 LOWER SERVICE COSTS AND HIGHER TURNAROUND TIME TO DRIVE MARKET
    • TABLE 44 CARRIER SCREENING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 10.4 FERTILITY CLINICS
    • 10.4.1 INCREASING NUMBER OF INFERTILE COUPLES AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES TO DRIVE MARKET
    • TABLE 45 CARRIER SCREENING MARKET FOR FERTILITY CLINICS, BY REGION, 2021-2028 (USD MILLION)
  • 10.5 OTHER END USERS
    • TABLE 46 CARRIER SCREENING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

11 CARRIER SCREENING MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 47 CARRIER SCREENING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 32 NORTH AMERICA: CARRIER SCREENING MARKET SNAPSHOT
    • TABLE 48 NORTH AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 50 NORTH AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 52 NORTH AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 53 NORTH AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • TABLE 54 NORTH AMERICA: CARRIER SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • 11.2.1 NORTH AMERICA: RECESSION IMPACT
    • 11.2.2 US
      • 11.2.2.1 Increasing number of genetic diseases and rising healthcare expenditure to drive market
    • TABLE 55 US: KEY MACROINDICATORS
    • TABLE 56 US: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 57 US: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 58 US: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 59 US: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 60 US: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 61 US: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.2.3 CANADA
      • 11.2.3.1 Increasing government and non-government funding to drive market
    • TABLE 62 CANADA: KEY MACROINDICATORS
    • TABLE 63 CANADA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 64 CANADA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 65 CANADA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 66 CANADA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 67 CANADA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 68 CANADA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3 EUROPE
    • TABLE 69 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
    • 11.3.1 EUROPE: RECESSION IMPACT
    • TABLE 70 EUROPE: CARRIER SCREENING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 71 EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 72 EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 73 EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 74 EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 75 EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 76 EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.2 GERMANY
      • 11.3.2.1 Increasing number of government initiatives and healthcare expenditures to drive market
    • TABLE 77 GERMANY: KEY MACROINDICATORS
    • TABLE 78 GERMANY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 79 GERMANY: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 80 GERMANY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 GERMANY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 82 GERMANY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 83 GERMANY: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.3 UK
      • 11.3.3.1 Rising prevalence of hematological disease and increasing number of accredited clinical laboratories to drive market
    • TABLE 84 UK: KEY MACROINDICATORS
    • TABLE 85 UK: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 86 UK: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 87 UK: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 88 UK: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 89 UK: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 90 UK: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.4 FRANCE
      • 11.3.4.1 Better healthcare infrastructure and higher expenditure for life science research to drive market
    • TABLE 91 FRANCE: KEY MACROINDICATORS
    • TABLE 92 FRANCE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 93 FRANCE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 94 FRANCE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 95 FRANCE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 96 FRANCE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 97 FRANCE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.5 ITALY
      • 11.3.5.1 Growing prevalence of chronic diseases and rising number of hospitals to drive market
    • TABLE 98 ITALY: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 99 ITALY: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 100 ITALY: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 ITALY: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 102 ITALY: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 103 ITALY: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.6 SPAIN
      • 11.3.6.1 Increasing prevalence of rare genetic diseases and rising availability of research funding to drive market
    • TABLE 104 SPAIN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 105 SPAIN: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 106 SPAIN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 107 SPAIN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 108 SPAIN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 109 SPAIN: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 110 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
    • TABLE 111 REST OF EUROPE: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 112 REST OF EUROPE: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 113 REST OF EUROPE: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 REST OF EUROPE: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 115 REST OF EUROPE: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 116 REST OF EUROPE: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4 ASIA PACIFIC
    • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 33 ASIA PACIFIC: CARRIER SCREENING MARKET SNAPSHOT
    • TABLE 117 ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 121 ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 122 ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.2 INDIA
      • 11.4.2.1 Growing incidence of rare diseases and declining fertility rates to drive market
    • TABLE 123 INDIA: KEY MACROINDICATORS
    • TABLE 124 INDIA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 125 INDIA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 126 INDIA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 127 INDIA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 128 INDIA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 129 INDIA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.3 CHINA
      • 11.4.3.1 Rising focus on vaccine development and cancer research to drive market
    • TABLE 130 CHINA: KEY MACROINDICATORS
    • TABLE 131 CHINA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 132 CHINA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 133 CHINA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 134 CHINA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 135 CHINA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 136 CHINA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.4 JAPAN
      • 11.4.4.1 Rising geriatric population and growing government healthcare expenditure to drive market
    • TABLE 137 JAPAN: KEY MACROINDICATORS
    • TABLE 138 JAPAN: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 139 JAPAN: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 140 JAPAN: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 141 JAPAN: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 142 JAPAN: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 143 JAPAN: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 144 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 145 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 147 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 148 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 149 REST OF ASIA PACIFIC: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5 REST OF THE WORLD
    • 11.5.1 REST OF THE WORLD: RECESSION IMPACT
    • TABLE 150 REST OF THE WORLD: CARRIER SCREENING MARKET, BY PRODUCT & 2021-2028 (USD MILLION)
    • TABLE 151 REST OF THE WORLD: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 REST OF THE WORLD: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 153 REST OF THE WORLD: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 154 REST OF THE WORLD: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 155 REST OF THE WORLD: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.2 LATIN AMERICA
      • 11.5.2.1 Higher prevalence of genetic disorders and growing focus on reproductive healthcare services to drive market
    • TABLE 156 DEFINITION OF RARE DISEASES IN VARIOUS COUNTRIES
    • TABLE 157 LATIN AMERICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 158 LATIN AMERICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 159 LATIN AMERICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 160 LATIN AMERICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 161 LATIN AMERICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 162 LATIN AMERICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 11.5.3 MIDDLE EAST & AFRICA
    • TABLE 163 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 164 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 166 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 167 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 168 MIDDLE EAST & AFRICA: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
      • 11.5.3.1 GCC Countries
        • 11.5.3.1.1 Improved healthcare infrastructure and launch of genome projects to drive market
    • TABLE 169 GCC COUNTRIES: CARRIER SCREENING MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 170 GCC COUNTRIES: CARRIER SCREENING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 GCC COUNTRIES: CARRIER SCREENING MARKET FOR EXPANDED CARRIER SCREENING, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 172 GCC COUNTRIES: CARRIER SCREENING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 173 GCC COUNTRIES: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
    • TABLE 174 GCC COUNTRIES: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
    • TABLE 175 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CARRIER SCREENING MARKET
  • 12.3 MARKET SHARE ANALYSIS
    • TABLE 176 DEGREE OF COMPETITION: CARRIER SCREENING MARKET
  • 12.4 REVENUE SHARE ANALYSIS
    • FIGURE 34 REVENUE SHARE ANALYSIS OF KEY PLAYERS
  • 12.5 COMPANY EVALUATION MATRIX
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 35 COMPANY EVALUATION MATRIX, 2022
    • 12.5.5 COMPANY FOOTPRINT
    • TABLE 177 OVERALL COMPANY FOOTPRINT
    • TABLE 178 PRODUCT FOOTPRINT
    • TABLE 179 REGIONAL FOOTPRINT
  • 12.6 START-UP/SME EVALUATION MATRIX
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • FIGURE 36 START-UP/SME EVALUATION MATRIX, 2022
    • 12.6.5 COMPETITIVE BENCHMARKING
    • TABLE 180 DETAILED LIST OF KEY START-UPS/SMES IN CARRIER SCREENING MARKET
  • 12.7 COMPETITIVE SCENARIOS AND TRENDS
    • 12.7.1 KEY DEALS
    • TABLE 181 KEY DEALS, JANUARY 2020-DECEMBER 2023

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)**
    • 13.1.1 NATERA, INC.
    • TABLE 182 NATERA, INC.: COMPANY OVERVIEW
    • FIGURE 37 NATERA, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.2 QUEST DIAGNOSTICS INCORPORATED
    • TABLE 183 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW
    • FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2022)
    • 13.1.3 FULGENT GENETICS
    • TABLE 184 FULGENT GENETICS: COMPANY OVERVIEW
    • FIGURE 39 FULGENT GENETICS.: COMPANY SNAPSHOT (2022)
    • 13.1.4 INVITAE CORPORATION
    • TABLE 185 INVITAE CORPORATION: COMPANY OVERVIEW
    • FIGURE 40 INVITAE CORPORATION.: COMPANY SNAPSHOT (2022)
    • 13.1.5 EUROFINS SCIENTIFIC
    • TABLE 186 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 13.1.6 OPKO HEALTH, INC.
    • TABLE 187 OPKO HEALTH, INC.: COMPANY OVERVIEW
    • FIGURE 42 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.7 THERMO FISHER SCIENTIFIC INC.
    • TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 13.1.8 MYRIAD GENETICS, INC.
    • TABLE 189 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
    • FIGURE 44 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.9 ILLUMINA, INC.
    • TABLE 190 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
    • 13.1.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 191 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
    • FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
    • 13.1.11 CENTOGENE N.V.
    • TABLE 192 CENTOGENE N.V.: COMPANY OVERVIEW
    • FIGURE 47 CENTOGENE N.V.: COMPANY SNAPSHOT (2022)
    • 13.1.12 DIASORIN S.P.A.
    • TABLE 193 DIASORIN S.P.A.: COMPANY OVERVIEW
    • FIGURE 48 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
    • 13.1.13 BGI
    • TABLE 194 BGI: COMPANY OVERVIEW
    • 13.1.14 OTOGENETICS
    • TABLE 195 OTOGENETICS: COMPANY OVERVIEW
    • 13.1.15 GENETECH
    • TABLE 196 GENETECH: COMPANY OVERVIEW
  • 13.2 OTHER PLAYERS
    • 13.2.1 OXY-GEN LABORATORY LLC
    • TABLE 197 OXY-GEN LABORATORY LLC: COMPANY OVERVIEW
    • 13.2.2 MEDGENOME
    • TABLE 198 MEDGENOME: COMPANY OVERVIEW
    • 13.2.3 AMBRY GENETICS.
    • TABLE 199 AMBRY GENETICS: COMPANY OVERVIEW
    • 13.2.4 ASPER BIOGENE
    • TABLE 200 ASPER BIOGENE: COMPANY OVERVIEW
    • 13.2.5 LIFELABS GENETICS
    • TABLE 201 LIFELABS GENETICS: COMPANY OVERVIEW
    • 13.2.6 EASYDNA
    • TABLE 202 EASYDNA: COMPANY OVERVIEW
    • 13.2.7 LIFECELL
    • TABLE 203 LIFECELL: COMPANY OVERVIEW
    • 13.2.8 CNC PATH LAB
    • TABLE 204 CNC PATH LAB: COMPANY OVERVIEW
    • 13.2.9 SIGNATURE DIAGNOSTICS INC.
    • TABLE 205 SIGNATURE DIAGNOSTICS INC.: COMPANY OVERVIEW
    • 13.2.10 MITERA
    • TABLE 206 MITERA: COMPANY OVERVIEW
  • *Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS